Sinovac Biotech Stock Total Debt
Sinovac Biotech fundamentals help investors to digest information that contributes to Sinovac Biotech's financial success or failures. It also enables traders to predict the movement of Sinovac Stock. The fundamental analysis module provides a way to measure Sinovac Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sinovac Biotech stock.
Sinovac |
Sinovac Biotech Company Total Debt Analysis
Sinovac Biotech's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Sinovac Biotech Total Debt | 93.13 M |
Most of Sinovac Biotech's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinovac Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Sinovac Biotech has a Total Debt of 93.13 M. This is 96.61% lower than that of the Healthcare sector and 71.33% lower than that of the Biotechnology industry. The total debt for all United States stocks is 98.25% higher than that of the company.
Sinovac Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinovac Biotech's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sinovac Biotech could also be used in its relative valuation, which is a method of valuing Sinovac Biotech by comparing valuation metrics of similar companies.Sinovac Biotech is currently under evaluation in total debt category among related companies.
Sinovac Fundamentals
| Return On Equity | 11.03 | ||||
| Return On Asset | 4.53 | ||||
| Profit Margin | 10.02 % | ||||
| Operating Margin | 15.86 % | ||||
| Current Valuation | 614.58 M | ||||
| Shares Outstanding | 98.9 M | ||||
| Shares Owned By Insiders | 15.89 % | ||||
| Shares Owned By Institutions | 23.11 % | ||||
| Number Of Shares Shorted | 199.77 K | ||||
| Price To Earning | 48.65 X | ||||
| Price To Book | 2.29 X | ||||
| Price To Sales | 2.16 X | ||||
| Revenue | 213.17 M | ||||
| Gross Profit | 213.58 M | ||||
| EBITDA | 38.49 M | ||||
| Net Income | 15.35 M | ||||
| Cash And Equivalents | 176.72 M | ||||
| Cash Per Share | 1.79 X | ||||
| Total Debt | 93.13 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 2.98 X | ||||
| Book Value Per Share | 2.83 X | ||||
| Cash Flow From Operations | 22.17 M | ||||
| Short Ratio | 47.51 X | ||||
| Earnings Per Share | 0.13 X | ||||
| Number Of Employees | 910 | ||||
| Beta | 0.08 | ||||
| Market Capitalization | 460.25 M | ||||
| Total Asset | 202.98 M | ||||
| Retained Earnings | (8.28 M) | ||||
| Working Capital | 70.52 M | ||||
| Current Asset | 128.52 M | ||||
| Current Liabilities | 58 M | ||||
| Z Score | 3.4 |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Sinovac Stock
If you are still planning to invest in Sinovac Biotech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sinovac Biotech's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Stocks Directory Find actively traded stocks across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |